Repligen

Repligen

Yahoo Finance • 2 days ago

3 Unpopular Stocks Walking a Fine Line

3 Unpopular Stocks Walking a Fine Line Wall Street's bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps d... Full story

Yahoo Finance • 3 days ago

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-deficit hyperactivity disorder (ADHD).... Full story

Yahoo Finance • 3 days ago

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

Johnson & Johnson JNJ announced positive top-line data from a pivotal phase III study evaluating Caplyta (lumateperone) for treating manic episodes, with or without mixed features, in adults with bipolar I disorder. More on JNJ's Latest S... Full story

Yahoo Finance • 4 days ago

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthrit... Full story

Yahoo Finance • 4 days ago

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

Merck MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion recommending approval of a combination of its blockbuster PD-L1 inhibitor, Keytruda (pembr... Full story

Yahoo Finance • 4 days ago

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics CORT announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Lifyorli (relacorilant) in combination with nab-pac... Full story

Yahoo Finance • 15 days ago

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).... Full story

Yahoo Finance • 16 days ago

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjug... Full story

Yahoo Finance • 21 days ago

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie ABBV reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatme... Full story

Yahoo Finance • 23 days ago

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS). Remibrutinib is a highly selective oral Bruton's tyrosine kinase (BTK) inhibitor that blocks... Full story

Yahoo Finance • 23 days ago

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II study, which showed that the company's... Full story

Yahoo Finance • 24 days ago

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation. The randomized, double-blind, placebo-controlled phase III SUMMIT study is desi... Full story

Yahoo Finance • 24 days ago

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first... Full story

Yahoo Finance • 28 days ago

1 Profitable Stock on Our Buy List and 2 We Brush Off

1 Profitable Stock on Our Buy List and 2 We Brush Off Even if a company is profitable, it doesn't always mean it's a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their futu... Full story

Yahoo Finance • 29 days ago

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

It has been about a month since the last earnings report for Repligen (RGEN). Shares have added about 27.7% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading... Full story

Yahoo Finance • last month

J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA

Johnson & Johnson JNJ announced that the FDA has approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and above who are currently or have been previ... Full story

Yahoo Finance • last month

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

Quick Read MRK and MRNA's intismeran autogene beat Keytruda alone on recurrence-free survival in Phase 3 melanoma, though no specific efficacy numbers have been released yet. BNTX surged 21% on read-across excitement, while ILMN rose 16%... Full story

Yahoo Finance • last month

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

Acadia Pharmaceuticals ACAD announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and old... Full story

Yahoo Finance • last month

3 High-Flying Stocks with Warning Signs

3 High-Flying Stocks with Warning Signs "You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevat... Full story

Yahoo Finance • last month

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same s... Full story